Research Article Volume 10 Issue 3
Received: March 29, 2021 | Published: June 25, 2021
Artemether-lumefantrine (AL) is a first line artemisinin-based combination therapy (ACT) recommended by the National guideline for the treatment of malaria in Nigeria. However, numerous brands, with price discrepancy, abound in Nigerian drug market and some of them may be substandard, thereby, predisposing consumers to the problems of ineffectively treated malaria and drug resistance.
Keywords: artemether/lumefantrine, quality, Nigeria
©2021 , et al. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.